Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Natalia S. Nunes"'
Publikováno v:
Brain, Behavior, & Immunity - Health, Vol 19, Iss , Pp 100401- (2022)
Inflammatory bowel diseases (IBD) are chronic intestinal disorders characterized by dysregulated immune responses to resident microbiota in genetically susceptible hosts. The activation of the cholinergic system has been proposed for the treatment of
Externí odkaz:
https://doaj.org/article/3e188b7179b94fdaa27417499dee18bd
Autor:
Ashley D. Hadjis, Natalia S. Nunes, Shanzay M. Khan, Rochelle E. Fletcher, Alessandra de Paula Pohl, David J. Venzon, Michael A. Eckhaus, Christopher G. Kanakry
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Post-transplantation cyclophosphamide (PTCy) reduces the incidence and severity of graft-versus-host disease (GVHD), thereby improving the safety and accessibility of allogeneic hematopoietic cell transplantation (HCT). We have shown that PTCy works
Externí odkaz:
https://doaj.org/article/2353e45dfe2c40c589b13c56dc2a4754
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Post-transplantation cyclophosphamide (PTCy) has been highly successful at preventing severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT). The clinical application of this approach was b
Externí odkaz:
https://doaj.org/article/1b5bdf2296fb48c9b7606a160096a54c
Autor:
Rochelle E. Fletcher, Natalia S. Nunes, Michael T. Patterson, Natasha Vinod, Shanzay M. Khan, Suresh K. Mendu, Xianghong Li, Alessandra de Paula Pohl, Lucas P. Wachsmuth, Hyoyoung Choo-Wosoba, Michael A. Eckhaus, David J. Venzon, Christopher G. Kanakry
Publikováno v:
Blood Adv
Posttransplantation cyclophosphamide (PTCy), given on days +3 and +4, reduces graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT), but its immunologic underpinnings are not fully understood. In a T-cell–replet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f209404a429cedb4583d3435bde76cfb
https://doi.org/10.1182/bloodadvances.2022007026
https://doi.org/10.1182/bloodadvances.2022007026
Autor:
Michael T. Patterson, Shanzay M. Khan, Natalia S. Nunes, Rochelle E. Fletcher, Jing Bian, Ashley D. Hadjis, Michael A. Eckhaus, Suresh K. Mendu, Alessandra de Paula Pohl, David J. Venzon, Hyoyoung Choo-Wosoba, Kazusa Ishii, Haiying Qin, Terry J. Fry, Maggie Cam, Christopher G. Kanakry
Publikováno v:
Blood. 141:659-672
Relapse limits the therapeutic efficacy both of chimeric antigen receptor (CAR) T cells and allogeneic hematopoietic cell transplantation (allo-HCT). Patients may undergo these therapies sequentially to prevent or treat relapsed malignancy. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c01008114de1005258e673a76ca91af4
https://doi.org/10.1182/blood.2022016660
https://doi.org/10.1182/blood.2022016660
Autor:
Luigi D. Notarangelo, Alexandra F. Freeman, Jennifer S. Wilder, Veena Kapoor, Irini Sereti, Jeffrey I. Cohen, Harry L. Malech, Ronald E. Gress, Jennifer L. Sadler, Jennifer A. Kanakry, Ellen Carroll, Miranda M. Broadney, Jeremy J. Rose, Lauren R. Skeffington, Elizabeth Garabedian, Xiao-Yi Yan, Natalia S. Nunes, Amy P. Hsu, Seth M. Steinberg, Christopher G. Kanakry, Gulbu Uzel, Rochelle Fletcher, Steven M. Holland, Andrea Lisco, William G. Telford, Juan Gea-Banacloche, Nirali N. Shah, Mark Parta, Christa S. Zerbe, Daniel H. Fowler, Stephanie N. Hicks, Dimana Dimitrova, Thomas E. Hughes, Jenny E Blau
Publikováno v:
Biol Blood Marrow Transplant
Allogeneic blood or marrow transplantation (BMT) is a potentially curative therapy for patients with primary immunodeficiency (PID). Safe and effective reduced-intensity conditioning (RIC) approaches that are associated with low toxicity, use alterna
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad197fd92f19071d59ac226e6423628e
https://doi.org/10.1016/j.bbmt.2019.08.018
https://doi.org/10.1016/j.bbmt.2019.08.018
Autor:
Michael T. Patterson, Natalia S. Nunes, Lucas P. Wachsmuth, Amrit Panjabi, Rochelle E. Fletcher, Shanzay M. Khan, Dimana Dimitrova, Jennifer A. Kanakry, Leo Luznik, Christopher G. Kanakry
Publikováno v:
Blood advances. 6(17)
Mechanisms of T-cell survival after cytotoxic chemotherapy, including posttransplantation cyclophosphamide (PTCy), are not well understood. Here, we explored the impact of PTCy on human CD8+ T-cell survival and reconstitution, including what cellular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a27c91183cad426f9f1f07c07f00dbfc
https://pubmed.ncbi.nlm.nih.gov/35819449
https://pubmed.ncbi.nlm.nih.gov/35819449
Autor:
Ashley D, Hadjis, Natalia S, Nunes, Shanzay M, Khan, Rochelle E, Fletcher, Alessandra de Paula, Pohl, David J, Venzon, Michael A, Eckhaus, Christopher G, Kanakry
Publikováno v:
Frontiers in immunology. 13
Post-transplantation cyclophosphamide (PTCy) reduces the incidence and severity of graft-versus-host disease (GVHD), thereby improving the safety and accessibility of allogeneic hematopoietic cell transplantation (HCT). We have shown that PTCy works
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::100d2d4404b8c32346ecce6dd1e82297
https://pubmed.ncbi.nlm.nih.gov/35493453
https://pubmed.ncbi.nlm.nih.gov/35493453
Autor:
Christopher G. Kanakry, David Venzon, Natalia S. Nunes, Rochelle Fletcher, Michael Eckhaus, Michael T. Patterson, Suresh K. Mendu, Lucas P. Wachsmuth, Shanzay M. Khan
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S169-S170
The use of PTCy substantially lowers the rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT), but the mechanisms of its action are incompletely understood. Recently, we showed i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9c171a9385e09ce3eae6edf831018d0
https://doi.org/10.1016/j.bbmt.2019.12.031
https://doi.org/10.1016/j.bbmt.2019.12.031
Autor:
Fabiany da Costa Gonçalves, Fernanda Visioli, Natalia S. Nunes, Scott R. Burks, Joseph A. Frank, Parwathy Chandran, Maggie Sundby, Ana Helena da Rosa Paz
Publikováno v:
EBioMedicine
Background Ulcerative Colitis (UC) is an Inflammatory Bowel Disease (IBD) characterized by uncontrolled immune response, diarrhoea, weight loss and bloody stools, where sustained remission is not currently achievable. Dextran Sulphate Sodium (DSS)-in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c60fd3349f7dd5a931ba9be4e0491eb0